Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + cisplatin + pemetrexed + nivolumab + ipilimumab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen, often referred to as the CheckMate 9LA protocol, is a first-line chemo-immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC). It consists of two immune checkpoint inhibitors—nivolumab (a PD-1 inhibitor) and ipilimumab (a CTLA-4 inhibitor)—combined with two cycles of platinum-based chemotherapy (cisplatin or carboplatin) and pemetrexed (specifically for non-squamous histology). The regimen is designed to provide the rapid cytoreductive benefits of chemotherapy alongside the durable immune response associated with dual checkpoint blockade. The specific context provided relates to the PROMOTING study, an observational pharmacological trial led by IRCCS San Raffaele, which evaluates the impact of patient-reported outcome measurements (PROMs) on clinical outcomes in patients receiving this first-line therapy.
- Other names
- Nivolumab plus Ipilimumab with Platinum-Doublet ChemotherapyPROMOTING trial regimen
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on carboplatin + cisplatin + pemetrexed + nivolumab + ipilimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + cisplatin + pemetrexed + nivolumab + ipilimumab.